Federal Circuit Finds Wyeth Restenosis Claims Invalid As Not Enabled Mondaq News Alerts (registration) As summarized by the Federal Circuit, "[t]he defendants market stent products that elute everolimus and zotarolimus, two drugs that have the same macrocyclic ring as sirolimus but different substituents at the C–42 position." Wyeth urged a claim ... |
